Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
Induced Pluripotent Stem Cells in Neurodegenerative Diseases: Application for Therapy...
share announcement

Induced Pluripotent Stem Cells in Neurodegenerative Diseases: Application for Therapy and Disease Modeling

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".

Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 50433

Special Issue Editors

Dr. Claudio Soto

E-Mail Website
Guest Editor
Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA
Interests: protein misfolding diseases; neurodegenerative diseases; prions; Alzheimer’s disease; Parkinson’s disease; biomarkers; stem cells; cerebral organoids
Dr. Abhisek Mukherjee

E-Mail Website
Guest Editor
Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA
Interests: protein misfolding diseases; neurodegenerative diseases; prions; Alzheimer’s disease; Parkinson’s disease; biomarkers; stem cells; cerebral organoids

Special Issue Information

Dear Colleagues,

Neurodegenerative diseases (NDs) are a group of age-associated debilitating disorders that progressively destroy cognitive abilities, including memory, reasoning, judgment skills, and motor coordination, causing social seclusion and complete dependence on caregivers. The aged population is increasing globally. Currently, none of the major NDs have a disease-modifying therapy, and without a cure or effective treatment NDs are expected to impose a severe socioeconomic burden on society. The brain is an organ with low regeneration capacity, and when the clinical symptoms of NDs are manifested, a large number of neurons are already dead. For this reason, the development of effective treatments is a difficult task. In recent years, stem cells have received growing attention as a potential regenerative therapy for brain disorders. Some success with stem cell therapies has been reported, but a major problem with using heterologous stem cells is immune rejection, hindering the use of allogenic human cells for transplant. This is especially complicated in the case of NDs, in which the inflammatory processes underlying these disorders can present an intrinsically hostile environment to any allogenic graft. Patient-specific stem cells are now possible thanks to the generation of induced pluripotent stem cells (iPSCs) from patient somatic cells, which has been suggested as a new revolutionary step towards personalized medicine.

Another problem in the development of efficient therapies for NDs is the lack of highly predictable models to study the diseases and test the effect of potential therapies. Rodent models, currently used in NDs research, do not develop pathology naturally. Although transgenic mouse models over-expressing one or a few disease-associated human gene variants reproduce some aspects of the pathology, they are insufficient to reproduce the complete spectrum of human ND pathology. The methodology to reprogram terminally differentiated human cells into iPSCs and differentiate them into brain cells including neurons and glia has provided us a remarkable opportunity to understand disease pathology in human cells with the patient’s genetic makeup and develop regenerative therapies to recover brain damage. The recent development of methodology to generate 3D human brain-like tissue (brain organoids) from patient-derived iPSCs is beginning to revolutionize our understanding of human brain development and diseases.

In this Special Issue we will focus on the use of iPSCs as a new strategy for regenerative cellular therapy for NDs and on the production of 2D and 3D models of NDs.

Prof. Dr. Claudio Soto
Dr. Abhisek Mukherjee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • induced pluripotent stem cells (iPSCs)
  • cerebral organoids
  • neurodegenerative diseases
  • cellular therapy
  • disease modeling

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 6523 KiB  
Article
Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson’s Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology
by Xiaojun Diao, Fei Wang, Andrea Becerra-Calixto, Claudio Soto and Abhisek Mukherjee
Cells 2021, 10(9), 2402; https://doi.org/10.3390/cells10092402 - 13 Sep 2021
Cited by 11 | Viewed by 4513
Abstract
Accumulation of α-synuclein (α-syn) into Lewy bodies (LBs) and mitochondrial abnormalities are the two cardinal pathobiological features of Parkinson’s disease (PD), which are associated with the loss of dopaminergic neurons. Although α-syn accumulates in many different cellular and mouse models, these models generally [...] Read more.
Accumulation of α-synuclein (α-syn) into Lewy bodies (LBs) and mitochondrial abnormalities are the two cardinal pathobiological features of Parkinson’s disease (PD), which are associated with the loss of dopaminergic neurons. Although α-syn accumulates in many different cellular and mouse models, these models generally lack LB features. Here, we generated midbrain dopaminergic (mDA) neuronal cultures from induced pluripotent stem cells (iPSCs) derived from familial PD (fPD) patients and healthy controls. We show that mDA neuronal cultures from fPD patients with A53T mutation and α-syn gene (SNCA) triplication display pathological α-syn deposits, which spatially and morphologically resemble LBs. Importantly, we did not find any apparent accumulation of pathological α-syn in mDA neuronal culture derived from a healthy donor. Furthermore, we show that there are morphological abnormalities in the mitochondrial network in mDA neuronal cultures from fPD patients. Consequently, these cells were more susceptible to mitochondrial damage compared with healthy donor-derived mDA neuronal cultures. Our results indicate that the iPSC-derived mDA neuronal culture platform can be used to investigate the spatiotemporal appearance of LBs, as well as their composition, architecture, and relationship with mitochondrial abnormalities. Full article
(This article belongs to the Special Issue Induced Pluripotent Stem Cells in Neurodegenerative Diseases: Application for Therapy and Disease Modeling)
►▼ Show Figures

Figure 1

16 pages, 2359 KiB  
Article
Induced Pluripotent Stem Cells to Understand Mucopolysaccharidosis. I: Demonstration of a Migration Defect in Neural Precursors
by Silvin Lito, Adama Sidibe, Sten Ilmjarv, Patricie Burda, Matthias Baumgartner, Bernhard Wehrle-Haller, Karl-Heinz Krause and Antoine Marteyn
Cells 2020, 9(12), 2593; https://doi.org/10.3390/cells9122593 - 3 Dec 2020
Cited by 5 | Viewed by 2829
Abstract
Background: Mucopolysaccharidosis type I-Hurler (MPS1-H) is a severe genetic lysosomal storage disorder due to loss-of-function mutations in the IDUA gene. The subsequent complete deficiency of alpha l-iduronidase enzyme is directly responsible of a progressive accumulation of glycosaminoglycans (GAG) in lysosomes which [...] Read more.
Background: Mucopolysaccharidosis type I-Hurler (MPS1-H) is a severe genetic lysosomal storage disorder due to loss-of-function mutations in the IDUA gene. The subsequent complete deficiency of alpha l-iduronidase enzyme is directly responsible of a progressive accumulation of glycosaminoglycans (GAG) in lysosomes which affects the functions of many tissues. Consequently, MPS1 is characterized by systemic symptoms (multiorgan dysfunction) including respiratory and cardiac dysfunctions, skeletal abnormalities and early fatal neurodegeneration. Methods: To understand mechanisms underlying MPS1 neuropathology, we generated induced pluripotent stem cells (iPSC) from a MPS1-H patient with loss-of-function mutations in both IDUA alleles. To avoid variability due to different genetic background of iPSC, we established an isogenic control iPSC line by rescuing IDUA expression by a lentivectoral approach. Results: Marked differences between MPS1-H and IDUA-corrected isogenic controls were observed upon neural differentiation. A scratch assay revealed a strong migration defect of MPS1-H cells. Also, there was a massive impact of IDUA deficiency on gene expression (340 genes with an FDR < 0.05). Conclusions: Our results demonstrate a hitherto unknown connection between lysosomal degradation, gene expression and neural motility, which might account at least in part for the phenotype of MPS1-H patients. Full article
(This article belongs to the Special Issue Induced Pluripotent Stem Cells in Neurodegenerative Diseases: Application for Therapy and Disease Modeling)
►▼ Show Figures

Figure 1

17 pages, 3289 KiB  
Article
A Simple Differentiation Protocol for Generation of Induced Pluripotent Stem Cell-Derived Basal Forebrain-Like Cholinergic Neurons for Alzheimer’s Disease and Frontotemporal Dementia Disease Modeling
by Sonia Sanz Muñoz, Martin Engel, Rachelle Balez, Dzung Do-Ha, Mauricio Castro Cabral-da-Silva, Damian Hernández, Tracey Berg, Jennifer A. Fifita, Natalie Grima, Shu Yang, Ian P. Blair, Garth Nicholson, Anthony L. Cook, Alex W. Hewitt, Alice Pébay and Lezanne Ooi
Cells 2020, 9(9), 2018; https://doi.org/10.3390/cells9092018 - 2 Sep 2020
Cited by 28 | Viewed by 7617
Abstract
The study of neurodegenerative diseases using pluripotent stem cells requires new methods to assess neurodevelopment and neurodegeneration of specific neuronal subtypes. The cholinergic system, characterized by its use of the neurotransmitter acetylcholine, is one of the first to degenerate in Alzheimer’s disease and [...] Read more.
The study of neurodegenerative diseases using pluripotent stem cells requires new methods to assess neurodevelopment and neurodegeneration of specific neuronal subtypes. The cholinergic system, characterized by its use of the neurotransmitter acetylcholine, is one of the first to degenerate in Alzheimer’s disease and is also affected in frontotemporal dementia. We developed a differentiation protocol to generate basal forebrain-like cholinergic neurons (BFCNs) from induced pluripotent stem cells (iPSCs) aided by the use of small molecule inhibitors and growth factors. Ten iPSC lines were successfully differentiated into BFCNs using this protocol. The neuronal cultures were characterised through RNA and protein expression, and functional analysis of neurons was confirmed by whole-cell patch clamp. We have developed a reliable protocol using only small molecule inhibitors and growth factors, while avoiding transfection or cell sorting methods, to achieve a BFCN culture that expresses the characteristic markers of cholinergic neurons. Full article
(This article belongs to the Special Issue Induced Pluripotent Stem Cells in Neurodegenerative Diseases: Application for Therapy and Disease Modeling)
►▼ Show Figures

Figure 1

22 pages, 28472 KiB  
Article
Establishment of an in Vitro Human Blood-Brain Barrier Model Derived from Induced Pluripotent Stem Cells and Comparison to a Porcine Cell-Based System
by Annalise Di Marco, Domenico Vignone, Odalys Gonzalez Paz, Ivan Fini, Maria Rosaria Battista, Antonella Cellucci, Elena Bracacel, Giulio Auciello, Maria Veneziano, Vinod Khetarpal, Mark Rose, Alessandro Rosa, Isabelle Gloaguen, Edith Monteagudo, Todd Herbst, Celia Dominguez and Ignacio Muñoz-Sanjuán
Cells 2020, 9(4), 994; https://doi.org/10.3390/cells9040994 - 16 Apr 2020
Cited by 31 | Viewed by 6616
Abstract
The blood-brain barrier (BBB) is responsible for the homeostasis between the cerebral vasculature and the brain and it has a key role in regulating the influx and efflux of substances, in healthy and diseased states. Stem cell technology offers the opportunity to use [...] Read more.
The blood-brain barrier (BBB) is responsible for the homeostasis between the cerebral vasculature and the brain and it has a key role in regulating the influx and efflux of substances, in healthy and diseased states. Stem cell technology offers the opportunity to use human brain-specific cells to establish in vitro BBB models. Here, we describe the establishment of a human BBB model in a two-dimensional monolayer culture, derived from human induced pluripotent stem cells (hiPSCs). This model was characterized by a transendothelial electrical resistance (TEER) higher than 2000 Ω∙cm2 and associated with negligible paracellular transport. The hiPSC-derived BBB model maintained the functionality of major endothelial transporter proteins and receptors. Some proprietary molecules from our central nervous system (CNS) programs were evaluated revealing comparable permeability in the human model and in the model from primary porcine brain endothelial cells (PBECs). Full article
(This article belongs to the Special Issue Induced Pluripotent Stem Cells in Neurodegenerative Diseases: Application for Therapy and Disease Modeling)
►▼ Show Figures

Figure 1

Review

Jump to: Research

34 pages, 2199 KiB  
Review
Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges
by Elizabeth Ford, Jodie Pearlman, Travis Ruan, John Manion, Matthew Waller, Gregory G. Neely and Leslie Caron
Cells 2020, 9(11), 2517; https://doi.org/10.3390/cells9112517 - 20 Nov 2020
Cited by 52 | Viewed by 10473
Abstract
Neurodegenerative diseases are characterized by irreversible cell damage, loss of neuronal cells and limited regeneration potential of the adult nervous system. Pluripotent stem cells are capable of differentiating into the multitude of cell types that compose the central and peripheral nervous systems and [...] Read more.
Neurodegenerative diseases are characterized by irreversible cell damage, loss of neuronal cells and limited regeneration potential of the adult nervous system. Pluripotent stem cells are capable of differentiating into the multitude of cell types that compose the central and peripheral nervous systems and so have become the major focus of cell replacement therapies for the treatment of neurological disorders. Human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC)-derived cells have both been extensively studied as cell therapies in a wide range of neurodegenerative disease models in rodents and non-human primates, including Parkinson’s disease, stroke, epilepsy, spinal cord injury, Alzheimer’s disease, multiple sclerosis and pain. In this review, we discuss the latest progress made with stem cell therapies targeting these pathologies. We also evaluate the challenges in clinical application of human pluripotent stem cell (hPSC)-based therapies including risk of oncogenesis and tumor formation, immune rejection and difficulty in regeneration of the heterogeneous cell types composing the central nervous system. Full article
(This article belongs to the Special Issue Induced Pluripotent Stem Cells in Neurodegenerative Diseases: Application for Therapy and Disease Modeling)
►▼ Show Figures

Graphical abstract

25 pages, 2509 KiB  
Review
Development and Differentiation of Midbrain Dopaminergic Neuron: From Bench to Bedside
by Mengmeng Wang, King-Hwa Ling, Jun Jie Tan and Cheng-Biao Lu
Cells 2020, 9(6), 1489; https://doi.org/10.3390/cells9061489 - 18 Jun 2020
Cited by 32 | Viewed by 17314
Abstract
Parkinson’s Disease (PD) is a neurodegenerative disorder affecting the motor system. It is primarily due to substantial loss of midbrain dopamine (mDA) neurons in the substantia nigra pars compacta and to decreased innervation to the striatum. Although existing drug therapy available can relieve [...] Read more.
Parkinson’s Disease (PD) is a neurodegenerative disorder affecting the motor system. It is primarily due to substantial loss of midbrain dopamine (mDA) neurons in the substantia nigra pars compacta and to decreased innervation to the striatum. Although existing drug therapy available can relieve the symptoms in early-stage PD patients, it cannot reverse the pathogenic progression of PD. Thus, regenerating functional mDA neurons in PD patients may be a cure to the disease. The proof-of-principle clinical trials showed that human fetal graft-derived mDA neurons could restore the release of dopamine neurotransmitters, could reinnervate the striatum, and could alleviate clinical symptoms in PD patients. The invention of human-induced pluripotent stem cells (hiPSCs), autologous source of neural progenitors with less ethical consideration, and risk of graft rejection can now be generated in vitro. This advancement also prompts extensive research to decipher important developmental signaling in differentiation, which is key to successful in vitro production of functional mDA neurons and the enabler of mass manufacturing of the cells required for clinical applications. In this review, we summarize the biology and signaling involved in the development of mDA neurons and the current progress and methodology in driving efficient mDA neuron differentiation from pluripotent stem cells. Full article
(This article belongs to the Special Issue Induced Pluripotent Stem Cells in Neurodegenerative Diseases: Application for Therapy and Disease Modeling)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop